Inhibition of KMT2D promotes the metabolic transition to aerobic glycolysis by regulating glucose transporter 3 (SLC2A3), increasing the aerobic glycolysis rate and changing the lipid composition of pancreatic cancer cells. The gene discussed is KMT2D; the disease is familial pancreatic carcinoma.